Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

About this update from Dianthus Therapeutics, Inc.

NEW YORK and WALTHAM, Mass. , Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and presentations by Marino Garcia , Chief Executive Officer, at the following healthcare investor conferences during the month of February: Guggenheim SMID Cap Biotech Conference – Fireside chat on February 6 at 9:00 a.m. ET in New York City Oppenheimer 35th Annual Healthcare Life Sciences Conference – Fireside chat on February 12 at 3:20 p.m. ET , taking place virtually Live webcasts of the Company’s presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website . About Dianthus Therapeutics Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass. , Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . Contact Jennifer Davis Ruff Dianthus Therapeutics [email protected] Source: Dianthus Therapeutics, Inc.

View stock analysis, news, and events for Dianthus Therapeutics, Inc.